Protein tyrosine phosphatase SHP2 mediates chronic insulin-induced endothelial inflammation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 8, 2012, Pages 1943-1950

  Giri, Hemant ^a   Muthuramu, Ilayaraja ^a   Dhar, Monalisa ^a   Rathnakumar, K ^a   Ram, Uma ^b   Dixit, Madhulika ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^b Seethapathy Clinic   (India)

Author keywords

arginase II; chronic hyperinsulinemia; endothelial inflammation; NO; SHP2

Indexed keywords

8 HYDROXY 7 (6 SULFONAPTHALEN 2 YL)DIAZENYLQUINOLINE 5 SULFONIC ACID; ARGINASE; ARGINASE 2; CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEIN TYROSINE PHOSPHATASE SHP 2; QUINOLINE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ARGINASE; CELLS, CULTURED; CHRONIC DISEASE; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INSULIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84864280255     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.239251     Document Type: Article

References (51)

1. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010;459:793-806.
2. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res. 1996;33:181-194. (Pubitemid 26164469)
3. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007;4:84-88. (Pubitemid 47167491)
4. Li G, Barrett EJ, Ko SH, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology. 2009;150:3475-3482.
5. Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia. 2004;47:532-536. (Pubitemid 38491250)
6. Madonna R, Massaro M, De Caterina R. Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. Biochim Biophys Acta. 2008;1782:511-516.
7. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-293. (Pubitemid 36776291)
8. Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 2008;13:4925-4932. (Pubitemid 351599646)
9. Jin ZG, Wong C, Wu J, Berk BC. Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells. J Biol Chem. 2005;280:12305-12309.
10. Dixit M, Loot AE, Mohamed A, Fisslthaler B, Boulanger CM, Ceacareanu B, Hassid A, Busse R, Fleming I. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress. Circ Res. 2005;97:1236-1244.
11. Li W, Nishimura R, Kashishian A, Batzer AG, Kim WJ, Cooper JA, Schlessinger J. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 1994;14:509-517.
12. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG. Protein-tyrosine- phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci USA. 1994;91:7335-7339.
13. Cunnick JM, Mei L, Doupnik CA, Wu J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem. 2001;276:24380-24387.
14. Delahaye L, Rocchi S, Van Obberghen E. Potential involvement of FRS2 in insulin signaling. Endocrinology. 2000;141:621-628. (Pubitemid 32250486)
15. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22:1251-1267. (Pubitemid 47470319)
16. Takada T, Matozaki T, Takeda H, Fukunaga K, Noguchi T, Fujioka Y, Okazaki I, Tsuda M, Yamao T, Ochi F, Kasuga M. Roles of the complex formation of SHPS-1 with SHP-2 in insulin-stimulated mitogen-activated protein kinase activation. J Biol Chem. 1998;273:9234-9242. (Pubitemid 28176215)
17. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem. 2003;278:41677-41684. (Pubitemid 37310425)
18. Stein-Gerlach M, Kharitonenkov A, Vogel W, Ali S, Ullrich A. Protein-tyrosine phosphatase 1D modulates its own state of tyrosine phosphorylation. J Biol Chem. 1995;270:24635-24637.
19. MacGillivray M, Herrera-Abreu MT, Chow CW, Shek C, Wang Q, Vachon E, Feng GS, Siminovitch KA, McCulloch CA, Downey GP. The protein tyrosine phosphatase SHP-2 regulates interleukin-1-induced ERK activation in fibroblasts. J Biol Chem. 2003;278:27190-27198. (Pubitemid 36876875)
20. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:126-129.
21. Yuan L, Yu WM, Yuan Z, Haudenschild CC, Qu CK. Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response. J Biol Chem. 2003;278:15208-15216. (Pubitemid 36799856)
22. Pfau S, Leitenberg D, Rinder H, Smith BR, Pardi R, Bender Jr. Lymphocyte adhesion-dependent calcium signaling in human endothelial cells. J Cell Biol. 1995;128:969-978.
23. Wang CZ, Su HW, Hsu YC, Shen MR, Tang MJ. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol Biol Cell. 2006;17:2839-2852.
24. Chang CI, Zoghi B, Liao JC, Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J Immunol. 2000;165:2134-2141. (Pubitemid 30643163)
25. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005;62:1539-1544. (Pubitemid 41434558)
26. Siklova-Vitkova M, Polak J, Klimcakova E, Vrzalova J, Hejnova J, Kovacikova M, Kovacova Z, Bajzova M, Rossmeislova L, Hnevkovska Z, Langin D, Stich V. Effect of hyperinsulinemia and very-low-calorie diet on interstitial cytokine levels in subcutaneous adipose tissue of obese women. Am J Physiol Endocrinol Metab. 2009;297:E1154-E1161.
27. Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol. 2006;70:562-570. (Pubitemid 44092317)
28. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 1997;9:193-204. (Pubitemid 27135987)
29. Osawa M, Itoh S, Ohta S, Huang Q, Berk BC, Marmarosh NL, Che W, Ding B, Yan C, Abe J. ERK1/2 associates with the c-Met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1): role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation. J Biol Chem. 2004;279:29691-29699. (Pubitemid 38915852)
30. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009;157:922-930.
31. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet. 1989;1:1356-1359. (Pubitemid 19151955)
32. Hellman B, Gylfe E, Grapengiesser E, Dansk H, Salehi A. Insulin oscillations-clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release. Lakartidningen. 2007;104:2236-2239.
33. Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules. J Clin Endocrinol Metab. 2000;85:1748-1751. (Pubitemid 32269269)
34. Kashyap SR, Belfort R, Cersosimo E, Lee S, Cusi K. Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects. J Cardiometab Syndr. 2008;3:141-146.
35. Lu W, Shen K, Cole PA. Chemical dissection of the effects of tyrosine phosphorylation of SHP-2. Biochemistry. 2003;42:5461-5468. (Pubitemid 36560443)
36. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science. 1993;259:1611-1614. (Pubitemid 23114640)
37. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell. 2001;8:759-769. (Pubitemid 33030210)
38. Bjelakovic G, Sokolovic D, Ljiljana S, Kocic G, Jevtovic T, Stojanovic I, Ilic M, Bjelakovic L, Zivic S, Pavlovic D, Nikolic J, Basic J. Arginase activity and magnesium levels in blood of children with diabetes mellitus. J Basic Clin Physiol Pharmacol. 2009;20:319-334.
39. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res. 2008;102:95-102.
40. Salimuddin, Upadhyaya, KC, Baquer NZ. Effects of vanadate on expression of liver arginase in experimental diabetic rats. IUBMB Life. 1999;48:237-240. (Pubitemid 29518818)
41. Goldstein BJ. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor. 1993;3:1-15.
42. Meyerovitch J, Backer JM, Kahn CR. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J Clin Invest. 1989;84:976-983. (Pubitemid 19228372)
43. Begum N, Sussman KE, Draznin B. Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities. Diabetes. 1991;40:1620-1629.
44. Boylan JM, Brautigan DL, Madden J, Raven T, Ellis L, Gruppuso PA. Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats. J Clin Invest. 1992;90:174-179.
45. McGuire MC, Fields RM, Nyomba BL, Raz I, Bogardus C, Tonks NK, Sommercorn J. Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. Diabetes. 1991;40:939-942.
46. Zheng H, Alter S, Qu CK. SHP-2 tyrosine phosphatase in human diseases. Int J Clin Exp Med. 2009;2:17-25.
47. Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood. 2005;105:3737-3742. (Pubitemid 40628224)
48. Jakob S, Schroeder P, Lukosz M, Büchner N, Spyridopoulos I, Altschmied J, Haendeler J. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J Biol Chem. 2008;283:33155-33161.
49. Chughtai N, Schimchowitsch S, Lebrun JJ, Ali S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem. 2002;277:31107-31114. (Pubitemid 34970816)
50. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
51. Shah DI, Singh M. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction. Vascul Pharmacol. 2006;44:177-182. (Pubitemid 43183666)